Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: antiviral vaccines - Profectus BioSciences

Drug Profile

Research programme: antiviral vaccines - Profectus BioSciences

Alternative Names: Chikungunya virus vaccine - Profectus; filovirus MCM - Profectus; HCV vaccine - Profectus BioSciences; HPV vaccine - Profectus BioSciences; HSV vaccine - Profectus BioSciences; Lassa fever vaccine - Profectus; Preventative HIV rVSV vaccine - Profectus; rVSV Marburg vaccine; rVSV-Ebola vaccine - Profectus; rVSV-Lassa; rVSV-QUAD; rVSV-Sudan; rVSV-VHF; rVSVN4CT1 Z Ebola; VesiculoVax rVSV-vectored Ebola/Marburg vaccine; VesiculoVax™-EEEV; VesiculoVax™-VEEV; Z EboV rVSVN4CT1

Latest Information Update: 13 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Profectus Biosciences
  • Developer Emergent BioSolutions; Profectus Biosciences; University of Texas Medical Branch
  • Class AIDS vaccines; DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Marburg virus disease; Venezuelan equine encephalomyelitis; Zika virus infection
  • Research Lassa fever
  • No development reported Viral infections

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for preclinical development in Viral-infections in USA (Parenteral)
  • 28 Jan 2019 No recent reports of development identified for preclinical development in Viral-infections(Prevention) in USA (Parenteral)
  • 16 Aug 2018 CEPI enters into a collaboration with Emergent BioSolutions and Profectus for development of Lassa virus vaccine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top